Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Launches Analysis Research & Development

Purple Patch For Pharma/Biotech R&D As NAS Launches Reach Record High

  • Analysis

Executive Summary

The pharma and biotech industries enjoyed their most productive year since the turn of the century in terms of number of novel products launched worldwide in 2018.

You may also be interested in...



Lynparza Gets US OK For Pancreatic Cancer

The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.

Podcast: Best BioPharma Books of 2019

Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.

 

J&J’s Spravato Gets EU Okay For Drug-Resistant Depression

Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.

Table

View full table

Topics

Related Companies

Tags:
Launches Analysis Research & Development
UsernamePublicRestriction

Register

SC125025

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By